OMA3
1.11.2022 20:46:43 CET | Business Wire | Press release
Today, OMA3™ (Open Metaverse Alliance), an association based in Zug, Switzerland, is announcing open membership to its first working groups at Web Summit, Europe’s largest tech conference.
Initial working group participants include some of the biggest and most innovative names in the space such as Animoca Brands, Alien Worlds, Dapper Labs, MetaMetaverse, SPACE Metaverse, SuperWorld, The Sandbox, Upland, Voxels, Unstoppable Domains, and Wivity (the agent to the consortium).
One of the core values of the metaverse is celebrating the decentralization of not only assets but power and influence as well. OMA3 achieves this by ensuring virtual land, identities, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities. OMA3’s Portaling and Mapping Working Group will create standards that allow users to port between virtual worlds. The Asset Transfer Working Group will standardize infrastructure for moving digital assets between virtual worlds. The Legal Working Group will examine the protection and fair use of intellectual property in Web3 applications and monitor developments in the regulatory environment. Companies wishing to participate in these working groups are invited to join OMA3 as a Creator Member on its website- OMA3.org.
As the metaverse continues to grow and develop at a rapid pace, the association will continue to nurture an open, interoperable metaverse by launching more working groups in areas such as participant safety, privacy, and cybersecurity.
Dirk Lueth, Co-founder & Co-CEO, Upland, Founding Member and Chairperson of OMA3 said, “The vision of OMA3 is to move from a platform-controlled Web2-world to a user-centric Web3-Metaverse. To achieve this, we have formed an alliance of Web3 companies who want to solve interoperability challenges for the metaverse, and we aim to leverage the alliance’s knowledge and web3 native insight to help propose and set the operating standard for interoperability in the metaverse.”
Batis Samadian, Founder & CEO, SPACE, Founding Member, and Vice Chair of OMA3 said, “Decentralization and interoperability require coordination to be successful. We are pleased that the OMA3 idea we hatched in the early days has resonated so well with the industry.”
All members of OMA3 have a shared belief in an Open Metaverse without restraining walls, where individual platforms are interconnected and fully interoperable so users can move their digital assets freely across worlds. To realize this goal, OMA3 has been formed and looks forward to members joining its mission.
Sébastien Borget, Co-Founder and COO of The Sandbox and Founding Member of OMA3 said, “within the Open Metaverse, digital assets freely move across OMA3 virtual worlds, enjoying increased security and better asset tracking across worlds. With these shared standards, users will be able to take digital items that they own from one metaverse to another, enabling a universe of interconnected virtual worlds that prioritizes user experience and ownership over platform dominance and censorship.”
Saro McKenna, CEO of Alien Worlds and Founding Member of OMA3 said, “OMA3’s vision centers on striving to create an open metaverse that is also community run, decentralized and indexable, where users will be able to own and use their digital assets (e.g. NFTs), identity and reputation in a frictionless way across multiple platforms. In OMA3’s vision users are in control of their assets, not platform owners, while ideas and services are based on the foundation of decentralization and interoperability to optimize for individual freedom, social, economic, and other sustainable outcomes.”
OMA3 is committed to ensuring data is permissionless, interoperable, and fully user-controlled, with DAO governance-centered principles of inclusiveness, transparency, and decentralization. As such, OMA3 is open to all Web3 metaverse builders; companies can join as creators or community members. To learn more about participation, please visit www.oma3.org.
About OMA3
OMA3, (Open Metaverse Alliance) is a consortium comprised of leading metaverse native companies The Sandbox, Animoca Brands, Alien Worlds, Dapper Labs, Decentraland, MetaMetaverse, Space, SuperWorld, Upland, Voxels, Unstoppable Domains, and Wivity. OMA3 seeks to ensure virtual land, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities.
Twitter: twitter.com/oma3dao
Website: www.oma3.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom